How High Will Take-Two Stock Go?
Take-Two Interactive (NASDAQ:TTWO) is the video game development company behind…
Buy
58
TMDX Quote, Financials, Valuation and Earnings
Last price:
$123.49
Seasonality move
:
11.22%
Day range:
$121.30 - $125.94
52-week range:
$55.00 - $177.37
Dividend yield:
0%
P/E ratio:
91.18x
P/S ratio:
9.28x
P/B ratio:
15.75x
Volume:
2.1M
Avg. volume:
1.1M
1-year change:
-14.19%
Market cap:
$4.2B
Revenue:
$441.5M
EPS (TTM):
$1.36
Analysts' Opinion
-
Consensus RatingTransMedics Group has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $132.43, TransMedics Group has an estimated upside of 6.8% from its current price of $123.56.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $103.00 representing 16.94% downside risk from its current price of $123.56.
Fair Value
-
According to the consensus of 8 analysts, TransMedics Group has 6.8% upside to fair value with a price target of $132.43 per share.
TMDX vs. S&P 500
-
Over the past 5 trading days, TransMedics Group has underperformed the S&P 500 by -13.27% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
TransMedics Group does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
TransMedics Group has grown year-over-year revenues for 14 quarters straight. In the most recent quarter TransMedics Group reported revenues of $143.5M.
Earnings Growth
-
TransMedics Group has grown year-over-year earnings for 0 quarters straight. In the most recent quarter TransMedics Group reported earnings per share of $0.70.
Enterprise value:
4.4B
EV / Invested capital:
5.66x
Price / LTM sales:
9.28x
EV / EBIT:
68.32x
EV / Revenue:
9.00x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-69.52x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
51.15x
Gross Profit (TTM):
$290.3M
Return On Assets:
6.26%
Net Income Margin (TTM):
10.03%
Return On Equity:
23.22%
Return On Invested Capital:
6.8%
Operating Margin:
19.12%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $119.1M | $296.9M | $488.2M | $96.9M | $143.5M | |
| Gross Profit | $81.9M | $185.3M | $290.3M | $60M | $88.2M | |
| Operating Income | -$24.2M | -$14.2M | $52.5M | $12.4M | $27.4M | |
| EBITDA | -$20.1M | $12.8M | $85.9M | $20.3M | $36.3M | |
| Diluted EPS | -$0.95 | -$0.34 | $1.36 | $0.35 | $0.70 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $140.5M | $105.8M | $261.7M | $488.3M | $505.9M | |
| Total Assets | $145.8M | $124M | $287.1M | $723.8M | $837.5M | |
| Current Liabilities | $11.8M | $20.3M | $28.6M | $50.2M | $55.6M | |
| Total Liabilities | $48.1M | $64.1M | $94.5M | $564.4M | $571.2M | |
| Total Equity | $97.7M | $59.9M | $192.6M | $159.5M | $266.3M | |
| Total Debt | $34.8M | $35.3M | $58.8M | $507M | $510.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$36.1M | -$7.8M | $49.4M | -$3.4M | -$2.9M | |
| Cash From Investing | $43.1M | -$237.2M | -$112.2M | -$44.2M | -$27M | |
| Cash From Financing | $171.5M | $399.6M | $22.7M | $3.2M | $3M | |
| Free Cash Flow | -$47M | -$230.1M | -$63.2M | -$47.6M | -$29.9M | |
TMDX
Sector
Market Cap
$4.2B
$32.8M
Price % of 52-Week High
69.91%
46.34%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-15.05%
-35.67%
Beta (5-Year)
2.097
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$136.92
200-day SMA
Buy
Level
$96.86
Bollinger Bands (100)
Buy
Level
64.91 - 116.93
Chaikin Money Flow
Sell
Level
-18.8M
20-day SMA
Sell
Level
$132.57
Relative Strength Index (RSI14)
Sell
Level
45.61
ADX Line
Sell
Level
44.97
Williams %R
Buy
Level
-85.3175
50-day SMA
Buy
Level
$112.12
MACD (12, 26)
Buy
Level
5.84
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Sell
Level
-26.4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.7779)
Sell
CA Score
(Annual)
Level (-1.1196)
Sell
Beneish M-Score
(Annual)
Level (-1.9488)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (0.1074)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Stock Forecast FAQ
In the current month, TMDX has received 5 Buy ratings 3 Hold ratings, and 0 Sell ratings. The TMDX average analyst price target in the past 3 months is $132.43.
-
Where Will TransMedics Group Stock Be In 1 Year?
According to analysts, the consensus estimate is that TransMedics Group share price will rise to $132.43 per share over the next 12 months.
-
What Do Analysts Say About TransMedics Group?
Analysts are divided on their view about TransMedics Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that TransMedics Group is a Sell and believe this share price will drop from its current level to $103.00.
-
What Is TransMedics Group's Price Target?
The price target for TransMedics Group over the next 1-year time period is forecast to be $132.43 according to 8 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is TMDX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for TransMedics Group is a Buy. 5 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TMDX?
You can purchase shares of TransMedics Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase TransMedics Group shares.
-
What Is The TransMedics Group Share Price Today?
TransMedics Group was last trading at $123.49 per share. This represents the most recent stock quote for TransMedics Group. Yesterday, TransMedics Group closed at $123.56 per share.
-
How To Buy TransMedics Group Stock Online?
In order to purchase TransMedics Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Target’s Stock Be in 10 Years?
If you could hop into a time machine and land…
Why Did Stan Druckenmiller Buy DocuSign?
Billionaire Stanley Druckenmiller’s Duquesne Family Office portfolio is always worth…
Stock Ideas
Buy
64
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
37
RGC alert for Jun 21
Regencell Bioscience Holdings [RGC] is down 40.02% over the past day.
Buy
83
GMS alert for Jun 21
GMS [GMS] is up 23.79% over the past day.
Buy
57
QNTM alert for Jun 21
Quantum BioPharma [QNTM] is up 13.82% over the past day.
